Volume 87 Issue 48 | p. 19 | Concentrates
Issue Date: November 30, 2009

Novartis Licenses Incyte Therapies

Department: Business
Keywords: licensing, cancer, Novartis

Novartis has entered a licensing agreement giving it U.S. rights to drug discovery firm Incyte’s JAK inhibitor INCB18424, a treatment for the blood disease myelofibrosis in Phase III trials. It will also gain worldwide rights to Incyte’s early-stage cMET inhibitor INCB28060, a therapy targeting tumor invasion and drug resistance in certain cancers. Novartis will pay Incyte $150 million up front, an initial milestone payment of $60 million, and up to $1 billion in additional milestone payments

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment